完整後設資料紀錄
DC 欄位語言
dc.contributor.authorJuang, Jyuhn-Huarngen_US
dc.contributor.authorKuo, Chien-Hungen_US
dc.contributor.authorWu, Chun-Hsingen_US
dc.contributor.authorJuang, Charityen_US
dc.date.accessioned2019-04-03T06:40:29Z-
dc.date.available2019-04-03T06:40:29Z-
dc.date.issued2008-01-01en_US
dc.identifier.issn0963-6897en_US
dc.identifier.urihttp://dx.doi.org/10.3727/096368908786092766en_US
dc.identifier.urihttp://hdl.handle.net/11536/9889-
dc.description.abstractExendin-4 stimulates insulin secretion, suppresses glucagons secretion, increases beta-cell replication and neogenesis, and reduces beta-cell apoptosis. However, it has been shown that posttransplant exendin-4 treatment did not improve glucose homeostasis in diabetic mice transplanted with a large number of freshly isolated islets. The aim of this study was to test if exendin-4 is beneficial for hyperglycemic recipients with a marginal number of fresh islets. We transplanted 150 C57BL/6 mouse islets under the kidney capsule of inbred streptozotocin-diabetic mice, and then treated the recipients with and without exendin-4 for 6 weeks. Before and after transplantation, recipients' blood glucose, body weight, and intraperitoneal glucose tolerance test were measured. At 6 weeks, the grafts were removed to determine beta-cell mass. Blood glucose levels in both groups decreased progressively after transplantation, and the exendin-4-treated group had had lower blood glucose than controls since day 3. By 6 weeks, euglycemia was achieved more in mice treated with exendin-4 than in controls (100% vs. 62.5%, p = 0.018). The time to obtain normoglycemia was shorter in the exendin-4-treated group than in controls (12 +/- 8 vs. 29 +/- 13 days, p < 0.001). Blood glucose at 6 weeks was 123 +/- 18 and 170 +/- 62 mg/dl in the exendin-4-treated group and controls, respectively (p = 0.008). Additionally, the exendin-4- treated group had better glucose tolerance than controls at 2 and 4 weeks (p < 0.02). However, both groups exhibited increased body weight over time, and weight changes did not significantly differ between the two groups throughout the study period. At 6 weeks after transplantation, grafts in the exendin-4-treated group were more prominent and contained more insulin-stained cells than those of controls. They had 2.3-fold beta-cell mass of the graft compared with controls (0.30 +/- 0.11 vs. 0.13 +/- 0.03 mg, p = 0.012). These results indicate posttransplant exendin-4 treatment in the diabetic recipient with a marginal number of fresh islets expands graft beta-cell mass and improves transplantation outcome.en_US
dc.language.isoen_USen_US
dc.subjectdiabetes mellitusen_US
dc.subjectislet transplantationen_US
dc.subjectexendin-4en_US
dc.subjectbeta-cell massen_US
dc.titleExendin-4 treatment expands graft beta-cell mass in diabetic mice transplanted with a marginal number of fresh isletsen_US
dc.typeArticleen_US
dc.identifier.doi10.3727/096368908786092766en_US
dc.identifier.journalCELL TRANSPLANTATIONen_US
dc.citation.volume17en_US
dc.citation.issue6en_US
dc.citation.spage641en_US
dc.citation.epage647en_US
dc.contributor.department生物科技學系zh_TW
dc.contributor.departmentDepartment of Biological Science and Technologyen_US
dc.identifier.wosnumberWOS:000259340600006en_US
dc.citation.woscount17en_US
顯示於類別:期刊論文


文件中的檔案:

  1. 26ebb235d33e177a772ea49c4f1e3704.pdf

若為 zip 檔案,請下載檔案解壓縮後,用瀏覽器開啟資料夾中的 index.html 瀏覽全文。